September 23, 2005
Scotland: NEW lung cancer drug extends survivalTopics: Medicine
A NEW lung cancer drug that significantly increases the chances of a patient surviving more than a year was launched yesterday.
Tarceva, a pill taken orally, has been shown to increase one-year survival in lung cancer patients by 43 per cent.
The European Medicines Agency licensed the drug for non-small-cell lung cancer patients who have failed chemotherapy treatment.
Dr David Dunlop, of the Beatson Oncology Centre in Glasgow, said the drug might extend the life of about 450 Scots patients.
Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not recommended in that setting.
Tarceva has been shown to target HER1/EGFR(videos) and inhibit Tyrosine Kinase (TK) phosphorylation. EGFR is expressed on normal cells and cancer cells. Tarceva's mechanism of clinical antitumor action has not been fully characterized.
Posted by Richard at September 23, 2005 11:00 AM
Articles Related to Medicine:
- Scotland: NEW lung cancer drug extends survival - Sep 23, 2005